Drugs / CL2020 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04261335 | Mar 2020 → Sep 2021 | brain hypoxia - ischemia | Nagoya University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CL2020 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04261335 ↗ |
| Known as | CL2020 | “This study aims to assess the safety and tolerability of the allogenic human multilineage-differentiating stress-enduring cell (Muse cell)-based product (CL2020) cells in...” PMID 35473726 ↗ Apr 2022 |
| Modality | Cell therapy | “allogenic human multilineage-differentiating stress-enduring cell (Muse cell)-based product” PMID 35473726 ↗ Apr 2022 |
| Route | Intravenous | “A single intravenous injection of CL2020 cells will be administered between 5 and 14 days of age.” PMID 35473726 ↗ Apr 2022 |